Additionally, CHI3L1 may be associated with insulin resistance and obesity in the pathogenesis of NASH, and hepatic insulin sensitivity can be partially restored by parenteral given anti-Chi3L1 monotherapy (78). This evidence concerns the gene CHI3L1 and metabolic dysfunction-associated steatohepatitis.